In 2020, 42 products containing a total of 41 new active substances received an EU marketing authorization, a sharp increase on the 28 NAS-containing products that were cleared in 2019, and just short of the three-year peak of 45 seen in 2018.
Among the most high-profile products to be approved last year were Pfizer Inc./BioNTech SE’s Comirnaty, the first vaccine for COVID-19, and Gilead Sciences, Inc